Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 7INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Dermatologic 1

Conditions

Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × tetrathiomolybdate × Clear all
NCT00352742 2008-10-28

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Attenuon

Phase 1/2 Terminated
46 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00405574 2008-01-30

Study of ATN-224 in Patients With Prostate Cancer

Attenuon

Phase 2 Unknown
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT00383851 2007-12-06

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Attenuon

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡